Cathy D Vocke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6824855/publications.pdf

Version: 2024-02-01

32 papers	2,457 citations	361413 20 h-index	434195 31 g-index
33 all docs	33 docs citations	33 times ranked	3773 citing authors

#	Article	IF	Citations
1	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. Urology, 2022, 165, 170-177.	1.0	2
2	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. Urology, 2021, 149, 89-97.	1.0	22
3	Comprehensive characterization of Alu â€mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. Human Mutation, 2021, 42, 520-529.	2.5	6
4	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. Genes Chromosomes and Cancer, 2021, 60, 434-446.	2.8	10
5	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydrataseâ€“deficient renal cancer. Science Signaling, 2021, 14, .	3.6	64
6	A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. Journal of Medical Genetics, 2020, , jmedgenet-2020-107308.	3.2	8
7	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153.	1.6	39
8	Novel renal medullary carcinoma cell lines, <scp>UOK353</scp> and <scp>UOK360</scp>, provide preclinical tools to identify new therapeutic treatments. Genes Chromosomes and Cancer, 2020, 59, 472-483.	2.8	7
9	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. Journal of Clinical Oncology, 2020, 38, 5004-5004.	1.6	53
10	A phase II study of the selective MET kinase inhibitor INC280 in advanced papillary renal cell cancer.. Journal of Clinical Oncology, 2020, 38, 5075-5075.	1.6	2
11	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. Urology, 2019, 124, 91-97.	1.0	20
12	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
13	Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. Cellular and Molecular Life Sciences, 2018, 75, 939-963.	5.4	36
14	Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers. Oncotarget, 2018, 9, 10723-10733.	1.8	35
15	Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492.	2.8	21
16	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). Genes Chromosomes and Cancer, 2017, 56, 719-729.	2.8	14
17	Patient-specific factors influence somatic variation patterns in von Hippelâ€“Lindau disease renal tumours. Nature Communications, 2016, 7, 11588.	12.8	24
18	H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. Human Molecular Genetics, 2016, 26, ddw392.	2.9	17

#	Article	IF	Citations
19	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118.	2.1	35
20	Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birtâ€“Hoggâ€“DubÃ© tumors. Modern Pathology, 2015, 28, 1458-1469.	5.5	23
21	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	16.8	87
22	A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	3.4	135
23	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390.	0.4	55
24	Identification of intragenic deletions and duplication in the FLCN gene in Birtâ€Hoggâ€ÐubÃ© syndrome. Genes Chromosomes and Cancer, 2011, 50, 466-477.	2.8	50
25	UOK 262 cell line, fumarate hydratase deficient (FHâ¯/FHâ¯) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55.	1.0	131
26	High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-DubÃ©â€“Associated Renal Tumors. Journal of the National Cancer Institute, 2005, 97, 931-935.	6.3	213
27	EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEOBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. Journal of Urology, 2001, 165, 1329-1334.	0.4	79
28	Proteomic analysis of laser capture microdissected human prostate cancer andin vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.	2.4	246
29	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. , 2000, 21, 2235.		2
30	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.	2.4	7
31	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	5.9	487
32	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. Breast Journal, 1998, 4, 9-12.	1.0	4